Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia

Bone Marrow Transplantation

Volumn 26, Issue 7, 2000, Pages 711-716

  Kroger N ^a   Zabelina, T ^a   Sonnenberg, S ^a   Kruger W ^a   Renges, H ^a   Stute, N ^a   Finkenstein, F ^a   Mayer, U ^a   Holstein, K ^a   Fiedler, W ^a   Colberg, H ^b   Sonnen, R ^b   Kuse, R ^b   Braumann, D ^c   Metzner, B ^d   Del Valle, F ^d   Erttmann, R ^a   Kabisch, H ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

Author keywords

Busulfan; Conditioning regimen; Cyclophosphamide; Etoposide; Stem cell transplantation; VP 16

Indexed keywords

AMPHOTERICIN; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; IMMUNOGLOBULIN M; METHOTREXATE; METRONIDAZOLE; OFLOXACIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION; INTERSTITIAL PNEUMONIA; ISOGRAFT; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

EID: 0033765574     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702598     Document Type: Article

References (34)

1. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update
2. Varying intensity of postremission therapy in acute myeloid leukemia
3. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia
4. Allogeneic hematopoietic stem cell transplantation for acute leukemia
5. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen
6. Autologous bone marrow transplantation in acute myeloid leukemia
7. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
8. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia
9. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
10. High-dose cyclophosphamide, BCNU, and VP-16 as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia
11. Two epidophyllotoxin derivates VM 26 and VP16-213 in the treatment of leukemias, hematosarcomas, and lymphomas
12. VP 16-213 in acute myelogenous leukemia
13. High-dose VP 16-213 for treatment of patients with previously treated acute leukemia
14. Etoposide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer
15. Etoposide in leukemia, lymphoma and bone marrow transplantation
16. High-dose VP16-213 and autologous bone marrow transplantation for refractory malignancies-a phase I study
17. Escalating doses of etoposide with cyclophosphamide and fractionated TBI or busulfan conditioning for BMT
18. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation
19. Clinical manifestations of graft vs host disease in human recipients of marrow from HLA-matched sibling donors
20. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow
21. Regimen related toxicity in patients undergoing bone marrow transplantation
22. Non-parametric estimation from incomplete observations
23. Marrow transplantation for acute non-lymphomic leukemia after treatment with busulfan and cyclophosphamide
24. Bone marrow transplantation for leukemia following new busulfan and cyclophosphamide regime
25. BuCy(120) vs TBI/Cy to prepare allo-BMT for CR1 AML: A follow-up of a study from GEGMO
26. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia
27. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: A meta-analysis
28. Total body irradiation and high-dose etoposide: A new preparative regimen for bone marrow transplantation in patients with advanced hematological malignancies
29. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias
30. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first Oncology Group Study
31. Improved results of allogenic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy
32. Busulfan/etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with AnLL
33. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation
34. High-dose chemotherapy with busulfan, cyclophosphamide and VP 16 as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission